Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Souders Financial Advisors

Souders Financial Advisors lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.5% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 37,132 shares of the biopharmaceutical company’s stock after selling 4,844 shares during the quarter. Souders Financial Advisors’ holdings in Gilead Sciences were worth $2,400,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. BlackRock Inc. boosted its stake in Gilead Sciences by 12.2% during the first quarter. BlackRock Inc. now owns 124,723,133 shares of the biopharmaceutical company’s stock worth $8,060,854,000 after buying an additional 13,539,799 shares during the last quarter. Geode Capital Management LLC boosted its stake in Gilead Sciences by 3.0% during the first quarter. Geode Capital Management LLC now owns 20,671,306 shares of the biopharmaceutical company’s stock worth $1,332,764,000 after buying an additional 592,386 shares during the last quarter. Dodge & Cox boosted its stake in Gilead Sciences by 35.7% during the fourth quarter. Dodge & Cox now owns 17,107,888 shares of the biopharmaceutical company’s stock worth $996,706,000 after buying an additional 4,500,035 shares during the last quarter. Norges Bank acquired a new position in Gilead Sciences during the fourth quarter worth $767,548,000. Finally, UBS Asset Management Americas Inc. boosted its stake in Gilead Sciences by 4.6% during the fourth quarter. UBS Asset Management Americas Inc. now owns 8,997,053 shares of the biopharmaceutical company’s stock worth $524,168,000 after buying an additional 392,859 shares during the last quarter. 77.18% of the stock is currently owned by institutional investors.

GILD has been the topic of several recent analyst reports. SVB Leerink upped their price target on Gilead Sciences from $72.00 to $74.00 and gave the company an “outperform” rating in a research note on Friday, April 30th. Morgan Stanley upped their price target on Gilead Sciences from $81.00 to $83.00 and gave the company an “overweight” rating in a research note on Monday, May 3rd. Zacks Investment Research raised Gilead Sciences from a “sell” rating to a “hold” rating and set a $69.00 price target on the stock in a research note on Wednesday, May 5th. Sanford C. Bernstein upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $80.00 price objective on the stock in a report on Thursday, April 1st. Finally, Redburn Partners upgraded Gilead Sciences from a “neutral” rating to a “buy” rating in a report on Tuesday, March 30th. Ten investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Gilead Sciences has an average rating of “Buy” and a consensus target price of $99.22.

In other news, Director Richard James Whitley sold 20,282 shares of the stock in a transaction that occurred on Monday, May 3rd. The stock was sold at an average price of $64.57, for a total transaction of $1,309,608.74. Following the completion of the transaction, the director now directly owns 51,404 shares of the company’s stock, valued at approximately $3,319,156.28. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.12% of the stock is currently owned by company insiders.

Shares of NASDAQ GILD traded down $0.43 during trading hours on Wednesday, reaching $66.62. The stock had a trading volume of 159,987 shares, compared to its average volume of 7,994,507. The stock has a market capitalization of $83.55 billion, a price-to-earnings ratio of 291.53, a price-to-earnings-growth ratio of 0.63 and a beta of 0.38. The company has a debt-to-equity ratio of 1.55, a quick ratio of 1.18 and a current ratio of 1.37. Gilead Sciences, Inc. has a fifty-two week low of $56.56 and a fifty-two week high of $78.94. The business’s 50-day simple moving average is $66.85.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 29th. The biopharmaceutical company reported $2.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.06 by $0.02. The firm had revenue of $6.42 billion during the quarter, compared to analysts’ expectations of $6.78 billion. Gilead Sciences had a return on equity of 51.91% and a net margin of 1.18%. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.07 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 29th. Shareholders of record on Tuesday, June 15th will be given a dividend of $0.71 per share. The ex-dividend date is Monday, June 14th. This represents a $2.84 dividend on an annualized basis and a yield of 4.26%. Gilead Sciences’s payout ratio is 40.06%.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Further Reading: Do You Need a Fiduciary?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.